Fabtech Technologies Fair Value
Fabtech Technologies (FABTECH) average fair value is ₹140.16 across 5 valuation models — P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number, vs a current market price of ₹153.55 (-8.72%), fair value range ₹93.33–₹243.13. For live price and a broader fundamental view, visit Fabtech Technologies share price screener.
Fair Value Analysis Export
FABTECH Fair Value vs Current Price — Valuation Summary
FABTECH average fair value, fair value range, price gap and valuation status across 5 models: P/E Based Valuation, P/B Based Valuation, Price-to-Sales Valuation, Asset-Based Valuation, Benjamin Graham Number. Examine Fabtech Technologies quarterly earnings for recent quarterly revenue, profit and EPS trends.
P/E Based Valuation
P/B Based Valuation
Price-to-Sales Valuation
Asset-Based Valuation
Benjamin Graham Number
FABTECH Fair Value Analysis — Data Sources & Coverage
Fabtech Technologies financial data sources, valuation methods applied and sector benchmarks used — 2026 financial year. See FABTECH book value to compare market price against book value per share.
Available Data Sources: Financial statements, balance sheet data , sector comparisons.
Data Currency: Financial data is from the current year (2026).
FABTECH vs Healthcare Sector Peers — P/E, P/B & Market Cap
Fabtech Technologies P/E ratio, P/B ratio and market capitalisation vs Healthcare sector peers — relative valuation comparison.
| Company | Symbol | P/E Ratio | P/B Ratio | Market Cap (₹ Cr) |
|---|---|---|---|---|
| Murae Organisor | MURAE | 2.86 | 0.2 | ₹41 |
| Accretion Pharmaceuticals | ACCPL | 17.91 | 2.7 | ₹120 |
| Jeena Sikho Lifecare | JSLL | 40.38 | 23.07 | ₹7,944 |
| Par Drugs & Chemical | PAR | 8.2 | 0.96 | ₹103 |
| Aurobindo Pharma | AUROPHARMA | 25.16 | 2.5 | ₹87,806 |
Important Disclaimer
This fair value analysis is for informational and educational purposes only. The calculations are based on publicly available financial data and various valuation methodologies.
This analysis does not constitute investment advice, recommendations, or suggestions to buy, sell, or hold any securities. Past performance and financial data do not guarantee future results.
Please conduct your own research and consult with qualified financial advisors before making any investment decisions. Market conditions, company fundamentals, and other factors can significantly impact actual stock performance.